期刊文献+

白三烯B4受体1拮抗剂U75302对脓毒症小鼠细胞免疫与炎症反应的影响 被引量:4

Effects of U75302,blocker of leukotriene B4 receptor 1,on cellular immunity and inflammation in septic mice
下载PDF
导出
摘要 目的观察白三烯B4受体1(leukotriene B4receptor 1,LTB4-BLT1)拮抗剂U75302对脓毒症小鼠免疫功能的影响,探讨阻断白三烯B4受体1在脓毒症治疗中的意义。方法采用盲肠结扎穿孔术(cecal ligation and puncture,CLP)致脓毒症小鼠模型,将18只雄性C57BL/6小鼠随机分为假手术组(n=6)、CLP组(n=6)、CLP+腹腔注射U75302组(n=6)。手术后24h检测3组小鼠外周血中肿瘤坏死因子α(tumor necrosis factor-α,TNF-α)及白介素10(interleukin-10,IL-10)的水平,利用流式细胞术检测3组小鼠腹腔灌洗液中Gr-1+细胞的计数以及胸腺T淋巴细胞的凋亡情况。结果与CLP组相比,CLP+腹腔注射U75302组小鼠外周血中的TNF-α水平降低约43%(P<0.05),IL-10水平升高约88%(P<0.05),腹腔Gr-1+细胞计数降低(P<0.05),胸腺T淋巴细胞凋亡比例减少(P<0.01)。结论 LTB4-BLT1拮抗剂U75302可降低外周血TNF-α水平、提高IL-10水平、改善细胞免疫,可能干预脓毒症的炎症反应。 Objective To observe the influence of U75302,blocker of leukotriene B4receptor 1,on immune function in septic mice,so as to explore the implication of blocking leukotriene B4 receptor 1 for treatment of sepsis. Methods Experimental sepsis model was induced by cecal ligation and puncture(CLP).A total of 18male C57BL/6mice were randomly divided into sham group(n=6),CLP group(n=6)and CLP+ U75302intraperitoneal injection group(n=6).The peripheral blood cytokine tumor necrosis factor-α(TNF-α)and interleukin-10(IL-10)levels,peritoneal lavage fluid Gr-1+cell count and thymus T lymphocytes apoptosis were detected in mice of three groups 24hafter surgery.Results Compared with the CLP group,CLP + U75302intraperitoneal injection group had significantly reduced blood TNF-αlevel(by 43%,P< 0.05),significantly increased IL-10level(by 88%,P<0.05),signficantly decreased Gr-1+cell counts in peritoneal lavage fluid(P<0.05),and significantly decreased apoptosis of thymus T lymphocytes(P<0.01).Conclusion Blocking leukotriene B4receptor 1with U75302may decrease peripheral TNF-αlevel,increase IL-10level,and improve cellular immunity,which may be involved in inflammation of sepsis.
出处 《第二军医大学学报》 CAS CSCD 北大核心 2014年第3期246-250,共5页 Academic Journal of Second Military Medical University
关键词 脓毒症 白三烯B4受体1 白三烯拮抗剂 细胞免疫 炎症 sepsis leukotriene B4receptor 1 leukotriene antagonists cellular immunity inflammation
  • 相关文献

参考文献17

  • 1YokomizoT,IzumiT,ChangK,TakuwaY,ShimizuT.GproteincoupledreceptorforleukotrieneB4thatmediateschemotaxis[J].Nature,1997,387:620624.
  • 2OyoshiMK,HeR,LiY,MondalS,YoonJ,AfsharR,etal.LeukotrieneB4drivenneutrophilrecruitmenttotheskinisessentialforallergicskininflammation[J].Immunity,2012,37:747758.
  • 3MiyaharaN,OhnishiH,MatsudaH,MiyaharaS,TakedaK,KoyaT,etal.LeukotrieneB4receptor1expressionondendriticcellsisrequiredforthedevelopmentofTh2responsesandallergeninducedairwayhyperresponsiveness[J].JImmunol,2008,181:11701171.
  • 4HikijiH,IshiiS,YokomizoT,TakatoT,ShimizuT.AdistinctiveroleoftheleukotrieneB4receptorBLT1inosteoclasticactivityduringboneloss[J].Proc NatlAcadSciUSA,2009,106:2129421299.
  • 5ZhangSJ,DengY M,ZhuYL,DongX W,JiangJX,XieQ M.IntracerebroventricularinjectionofleukotrieneB4attenuatesantigeninducedasthmaticresponseviaBLT1receptorstimulatingHPAaxisinsensitizedrats[J].RespirRes,2010,11:39.
  • 6MarianE,BaraldoS,Visentin A,PapiA,Saetta M,FabbriLM,etal.UpregulatedmembraneandnuclearleukotrieneB4receptorsinCOPD[J].Chest,2006,129:15231530.
  • 7MathisSP,JalaVR,LeeDM,HaribabuB.NonredundantrolesforleukotrieneB4receptorsBLT1andBLT2ininflammatoryarthritis[J].JImmunol,2010,185:30493056.
  • 8UnsingerJ,McglynnM,KastenKR,HoekzemaAS,WatanabeE,MuenzerJT,etal.IL7promotesTcellviability,trafficking,andfunctionalityandimprovessurvivalinsepsis[J].JImmunol,2010,184:37683779.
  • 9ShimaokaM,ParkEJ.Advancesinunderstandingsepsis[J].EurJAnaesthesiolSuppl,2008,42:146153.
  • 10WangH,LiaoH,OchaniM,JustinianiM,LinX,YangL,etal.CholinergicagonistsinhibitHMGB1releaseandimprovesurvivalinexperimentalsepsis[J].NatMed,2004,10:12161221.

同被引文献40

  • 1王小兵,夏业军,潘怀富,丁淑如.APACHEII评分对219例重症急性肾衰竭病情程度及预后分析[J].疑难病杂志,2005,4(1):13-15. 被引量:2
  • 2王家葵,李傲,王慧,徐晓玉.正品大黄不同品种间泻下效价强度比较研究[J].中国中药杂志,2006,31(23):1987-1991. 被引量:44
  • 3刘清泉.对脓毒症中医病机特点及治法的认识[J].北京中医,2007,26(4):198-200. 被引量:210
  • 4Paul M,Shani V,Muchtar E,et al.Systematic review and meta-analysis of the efi cacy of appropriate empiric antibiotictherapy for sepsis[J].Antimierob Agents Chemother,2010,54(11):4851-4863.
  • 5Takeda,Akira S.Toll-like receptors in innate immunity[J].Int Immunol,2005,17(1):1-14.
  • 6Payen D,Marco J,Cavaillon JM,et al.Impact of continuous venovenous hemofilration On organ failure during the early phase of severe sepsis,A randomized controlled trial[J].Critical Care Medicine,2009,37(6):803-810.
  • 7Gogos CA,Drosou E,Bassaris HP,et al.Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis:a marker for prognosis and future therapeutic options[J].J Infec D,2000,181(1):176-180.
  • 8Dominic Snijders,Johannes M. A. Daniels,Casper S. de Graaff.Efficacy of Corticosteroids in Community-acquired Pneumonia A Randomized Double-Blinded Clinical Trial. American Journal of Respiratory and Critical Care Medicine . 2010
  • 9Paul Mical,Shani Vered,Muchtar Eli,Kariv Galia,Robenshtok Eyal,Leibovici Leonard.Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrobial Agents and Chemotherapy . 2010
  • 10Bone,RC,Balk,RA,Cerra,FB,Dellinger,RP,Fein,AM,Knaus,WA,Schein,RM,Sibbald,WJ.Definitions for sepsis and organ failure guidelines for the use of innovative therapies in sepsis. Chest . 1992

引证文献4

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部